Journal: Journal of thermal biology

Article Title: Effects of heat stress exposure on porcine muscle satellite cells.

doi: 10.1016/j.jtherbio.2023.103569

Figure Lengend Snippet: Fig. 4. Expression of myogenic transcription factors in PMSCs exposed to heat stress. (A) Immunostaining images of transcription factors in PMSCs. Cell nuclei were stained with DAPI (blue), Pax7 (green), and MyoD (red). (B, C) Changes in Pax7, MyoD, and MyoG protein levels in PMSCs by heat stress. (D) Gene expression of Pax7, MyoD, and MyoG in PMSCs by heat treatment. Values are presented as the mean ± SE. a-c Different letters represent statistically significant differences among treatment groups (p < 0.01). Scale bar, 50 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: These membranes were blocked with TBST buffer containing 5% skim milk for 1.5 h at room temperature, and then incubated with primary antibodies against GAPDH (1:5000, monoclonal, MA5-15738, Invitrogen), Bax (1:1000, monoclonal, sc-7480, Santa Cruz), Bcl-2 (1:1000, monoclonal, sc-7382, Santa Cruz), caspase3 (1:1000, monoclonal, NB100-56708, Novusbio), Pax7 (1:1000, monoclonal, DSHB), MyoD (1:1000, polyclonal, 18943-1-AP, Proteintech), MyoG (1:1000, J.

Techniques: Expressing, Immunostaining, Staining, Gene Expression

Journal:

Article Title: Strong Immunostaining for Myogenin in Rhabdomyosarcoma Is Significantly Associated with Tumors of the Alveolar Subclass

doi:

Figure Lengend Snippet: Representative staining for myogenin in embryonal and alveolar rhabdomyosarcoma. The embryonal rhabdomyosarcoma (top panels) in this figure was less than 10% positive for myogenin and was scored as (+), whereas most tumor cells (85–95%) in the alveolar rhabdomyosarcoma tumor (bottom panels) were homogeneously strongly positive for myogenin. This tumor was scored as (+++). Left: Lower magnification (original magnification, ×200). Right: Higher magnification (original magnification, ×400). ABC staining, methyl green counterstain.

Article Snippet: The monoclonal antibody to myogenin (Imgenex, San Diego, CA) was raised against glutathione S -transferase (GST)-myogenin fusion protein.

Techniques: Staining

Journal:

Article Title: Strong Immunostaining for Myogenin in Rhabdomyosarcoma Is Significantly Associated with Tumors of the Alveolar Subclass

doi:

Figure Lengend Snippet: Western blot analysis of myogenin expression in various small round cell tumor lines using the anti-myogenin monoclonal antibody. The antibody only reacts with a protein band corresponding to the molecular mass of myogenin (approximately 34 kd) in the Rh30 rhabdomyosarcoma cell lysate. All other small round cell tumor lysates were negative. Rh30, alveolar rhabdomyosarcoma cell line; PFSK-1A, primitive neuroectodermal tumor cell line; EB2, lymphoma cell line; SKNSH, neuroblastoma cell line; SJSA-1, Ewing’s sarcoma cell line.

Article Snippet: The monoclonal antibody to myogenin (Imgenex, San Diego, CA) was raised against glutathione S -transferase (GST)-myogenin fusion protein.

Techniques: Western Blot, Expressing

Journal:

Article Title: Strong Immunostaining for Myogenin in Rhabdomyosarcoma Is Significantly Associated with Tumors of the Alveolar Subclass

doi:

Figure Lengend Snippet: Western blot analysis for myogenin expression in a smaller subset of rhabdomyosarcoma specimens. Four of six alveolar rhabdomyosarcomas (lanes 8, 10, 11, and 12) were strongly positive for myogenin. One alveolar rhabdomyosarcoma (lane 7) was negative, and one alveolar tumor (lane 9) was weakly positive for myogenin. Three of six embryonal rhabdomyosarcomas (lanes 3, 4, and 6) were negative for myogenin, whereas two of six (lanes 2 and 5) were weakly positive. One embryonal rhabdomyosarcoma (lane 1), a posttreatment tumor, was strongly positive for myogenin. The blot was incubated with anti-myogenin monoclonal antibody. Reactivity was detected using a horseradish peroxidase-conjugated secondary antibody and visualized using a chemiluminescent substrate and exposure to photographic films.

Article Snippet: The monoclonal antibody to myogenin (Imgenex, San Diego, CA) was raised against glutathione S -transferase (GST)-myogenin fusion protein.

Techniques: Western Blot, Expressing, Incubation

Journal:

Article Title: Strong Immunostaining for Myogenin in Rhabdomyosarcoma Is Significantly Associated with Tumors of the Alveolar Subclass

doi:

Figure Lengend Snippet: Summary of Anti-Myogenin Staining in Embryonal and Alveolar Rhabdomyosarcomas

Article Snippet: The monoclonal antibody to myogenin (Imgenex, San Diego, CA) was raised against glutathione S -transferase (GST)-myogenin fusion protein.

Techniques: Staining

Journal:

Article Title: Strong Immunostaining for Myogenin in Rhabdomyosarcoma Is Significantly Associated with Tumors of the Alveolar Subclass

doi:

Figure Lengend Snippet: Analysis of an Additional Subset of Rhabdomyosarcomas for Quantitative Differences in Expression of Myogenin by Western Blot Analysis and Correlation with Immunohistochemical Staining Data

Article Snippet: The monoclonal antibody to myogenin (Imgenex, San Diego, CA) was raised against glutathione S -transferase (GST)-myogenin fusion protein.

Techniques: Expressing, Western Blot, Immunohistochemical staining, Staining

Journal:

Article Title: Strong Immunostaining for Myogenin in Rhabdomyosarcoma Is Significantly Associated with Tumors of the Alveolar Subclass

doi:

Figure Lengend Snippet: Immunohistochemical Staining for Myogenin in Embryonal and Alveolar Rhabdomyosarcomas

Article Snippet: The monoclonal antibody to myogenin (Imgenex, San Diego, CA) was raised against glutathione S -transferase (GST)-myogenin fusion protein.

Techniques: Immunohistochemical staining, Staining

Journal: Life Science Alliance

Article Title: SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis

doi: 10.26508/lsa.202201457

Figure Lengend Snippet: Resources and reagents used in this study.

Article Snippet: Myogenin antibody (MGN185) Alexa Fluor 647 , NOVUS , Cat# NBP2-33056AF647.

Techniques: Transduction, Control, Negative Control, Virus, Expressing, Construct, Recombinant, Flow Cytometry, Isolation, Software

Journal: Molecular Therapy. Nucleic Acids

Article Title: miR-324-5p Inhibits C2C12 cell Differentiation and Promotes Intramuscular Lipid Deposition through lncDUM and PM20D1

doi: 10.1016/j.omtn.2020.09.037

Figure Lengend Snippet: Overexpression of miR-324-5p Inhibits the Differentiation of C2C12 Myoblasts (A) The efficiency of miR-324-5p overexpression after agomiR-324-5p transfection compared with that of the negative control (NC) on day 6 of differentiation. (B) Immunofluorescence staining of muscle myosin heavy chain (MyHC) in C2C12 myoblasts. Scale bars, 300 μm. (C) The fusion index was assessed as the ratio of MyHC-positive cells to the total number of nuclei. (D) The RNA level of myogenesis-related genes, including Myo d , Myog , and Myhc , detected by quantitative real-time PCR after overexpression of miR-324-5p. (E) Western blot analysis of myogenesis-related proteins after overexpression of miR-324-5p. (F) Quantification of protein levels. The data are expressed as mean ± SD; n = 5. ∗p < 0.05, ∗∗p < 0.01.

Article Snippet: Membranes were then incubated overnight with primary antibodies as follows: anti-MYOD (Santa Cruz, Dallas, TX, USA), anti-MYOG (Novus Biologicals, CO, USA), anti-MyHC (Abcam, Cambridge, UK), anti-OCT4 (Santa Cruz), anti-ELOVL6 (Cell Signaling Technology), anti-ACC (Cell Signaling Technology), anti-p-ACC (Cell Signaling Technology), and anti-CPT1 (Santa Cruz Biotechnology).

Techniques: Over Expression, Transfection, Negative Control, Immunofluorescence, Staining, Real-time Polymerase Chain Reaction, Western Blot

Journal: Molecular Therapy. Nucleic Acids

Article Title: miR-324-5p Inhibits C2C12 cell Differentiation and Promotes Intramuscular Lipid Deposition through lncDUM and PM20D1

doi: 10.1016/j.omtn.2020.09.037

Figure Lengend Snippet: Inhibition of miR-324-5p Promotes C2C12 Myoblast Differentiation (A) The efficiency of miR-324-5p inhibition after antagomiR-324-5p transfection compared with that of the negative control (NA) on day 6 of differentiation. (B) Immunofluorescence staining of MyHC in C2C12 myoblasts. Scale bars, 300 μm. (C) The fusion index was assessed as the ratio of MyHC-positive cells to the total number of nuclei. (D) Quantitative real-time PCR was used to detect the expression of myogenesis-related genes, including Myo d , Myog , and Myhc , after inhibition of miR-324-5p. (E) Western blot analysis of myogenesis-related proteins after inhibition of miR-324-5p. (F) Quantification of protein levels. The data are expressed as mean ± SD; n = 5. ∗p < 0.05, ∗∗p < 0.01.

Article Snippet: Membranes were then incubated overnight with primary antibodies as follows: anti-MYOD (Santa Cruz, Dallas, TX, USA), anti-MYOG (Novus Biologicals, CO, USA), anti-MyHC (Abcam, Cambridge, UK), anti-OCT4 (Santa Cruz), anti-ELOVL6 (Cell Signaling Technology), anti-ACC (Cell Signaling Technology), anti-p-ACC (Cell Signaling Technology), and anti-CPT1 (Santa Cruz Biotechnology).

Techniques: Inhibition, Transfection, Negative Control, Immunofluorescence, Staining, Real-time Polymerase Chain Reaction, Expressing, Western Blot

Journal: Molecular Therapy. Nucleic Acids

Article Title: miR-324-5p Inhibits C2C12 cell Differentiation and Promotes Intramuscular Lipid Deposition through lncDUM and PM20D1

doi: 10.1016/j.omtn.2020.09.037

Figure Lengend Snippet: Summary Diagram Showing That miR-324-5p Inhibits C2C12 Myoblast Differentiation and Promotes Oleate-Induced Lipid Deposition in C2C12 Myoblasts DAG, diacylglycerol; TG, triglyceride; MyoG, myogenin; MyoD, myoblast determination protein; Dppa2, developmental pluripotency associated 2.

Article Snippet: Membranes were then incubated overnight with primary antibodies as follows: anti-MYOD (Santa Cruz, Dallas, TX, USA), anti-MYOG (Novus Biologicals, CO, USA), anti-MyHC (Abcam, Cambridge, UK), anti-OCT4 (Santa Cruz), anti-ELOVL6 (Cell Signaling Technology), anti-ACC (Cell Signaling Technology), anti-p-ACC (Cell Signaling Technology), and anti-CPT1 (Santa Cruz Biotechnology).

Techniques: